Apheresis in treatment of acute inflammatory demyelinating disorders

Mühlhausen, Johannes; Kitze, Bernd; Huppke, Peter; Müller, Gerhard A.; Koziolek, Michael

doi:10.1016/j.atherosclerosissup.2015.02.037

Cited by 26 publications

(31 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…regenerated rather than replaced). 7,93 In adults immunoadsorption has equivalent efficacy to TPE for myasthenic crises 94 and relapses of multiple sclerosis and neuromyelitis optica, 95 with equivalent or superior safety profiles. It is hoped that such systems can be more widely used in future.…”

Section: Priorities For Future Researchmentioning

confidence: 99%

Therapeutic plasma exchange in paediatric neurology: a critical review and proposed treatment algorithm

Eyre

Hacohen

Barton

et al. 2018

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

Section: Priorities For Future Researchmentioning

confidence: 99%

Therapeutic plasma exchange in paediatric neurology: a critical review and proposed treatment algorithm

Eyre

Hacohen

Barton

et al. 2018

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

“…Con respecto al déficit neurológico, al igual que lo descrito en la literatura, la mayor cantidad de pacientes desarrolló la sintomatología de forma aguda [17] . En lo relacionado con el déficit topográfico, se ha estimado que cerca del 50% de los pacientes presentan paraparesia, 80% a 94% presentan debilidad, parestesias y disestesias en banda; describiendo disfunción vesical en todos los casos [18] .…”

Section: Discussionunclassified

Caracterización de la mielitis transversa en un hospital referencia del sur colombiano

et al. 2017

View full text Add to dashboard Cite

Objetivo: caracterizar a los pacientes con diagnóstico de mielitis transversa (MT) en un hospital de referencia del sur de Colombia durante los años 2007 a 2013. Materiales y métodos: Estudio transversal. Se incluyeron todos los pacientes con diagnóstico de MT, según los criterios The Transverse Myelitis Consortium Working Group. Resultados: En total 21 casos de MT (1,3 casos/10 000 ingresos), el 66,7% en edades entre 15-30 años, 57,1% de género femenino; 81,0% agudos. Todos presentaron déficit motor, 52,4% disfunción vesical autonómica, 81,0% nivel sensitivo. Se documentaron hallazgos imagenológicos de MT en resonancia magnética nuclear en el 71,4% de los casos e hiperproteinorraquia en 50%. En el 66,7% la etiología fue desconocida, en los casos en quienes se logró determinar la etiología fue: herpes simple tipo 1 (9,5%), varicela zoster (9,5%), leucemia mieloide aguda (4,8%), lupus eritematoso sistémico (4,8%) y deficiencia de vitamina B12 (4,8%). Conclusiones: La MT es un importante problema de salud pública, es necesario considerar sus características clínicas, establecer las formas idiopáticas y reconocer etiologías infecciosas dado el impacto terapeutico y pronóstico.

show abstract

“…Other current therapeutic options include treatment with cyclophosphamide, which is often used if other immunomodulatory treatments have proven ineffective, or with rituximab, which depletes CD20 + B cells and has been reported to be particularly effective in disorders associated with IgG4 antibodies . In some instances, immunoadsorption apheresis has also been used …”

Section: Strategies To Remove Autoantibodies and Treat Antibody‐mediamentioning

confidence: 99%

“…143 In some instances, immunoadsorption apheresis has also been used. 144 A number of other therapeutic approaches are in development or in clinical trials, or currently approved only for other (often autoimmune) disorders. These include molecules to deplete BAFF (including atacicept 145 and belimumab 146 ), to block complement activation (e.g.…”

Section: Strategies To Remove Autoantibodies and Treat Antibody-mediamentioning

confidence: 99%

Autoantibodies and their potential roles in diseases of the nervous system

Beasley

Greer

2015

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Autoantibodies are found in many disorders of the nervous system, including diseases affecting the peripheral nervous system (e.g. Guillain-Barr e syndrome and other peripheral neuropathies), the central nervous system (e.g. neuromyelitis optica, multiple sclerosis and limbic encephalitis) and the neuromuscular junction (e.g. myasthenia gravis), as well as in neuropsychiatric disorders and in paraneoplastic syndromes. Some of these antibodies are likely to play an important pathogenic role in disease development, whereas others might be useful biomarkers for disease. In the present review, the features of an autoantibody that enable it to be pathogenic (e.g. the antibody isotype and the target antigen against which the antibody is directed) and some of the different mechanisms by which pathogenic autoantibodies could act will be discussed. These mechanisms include antibody-mediated cell lysis, opsonization of target proteins for attack by macrophages, crosslinking of Fc receptors, blocking or destroying receptors involved in neurotransmission or cellular homeostasis, and blocking of repair mechanisms such as remyelination. Examples will be given of diseases where these antibody-mediated mechanisms are known or thought to be active. Finally, approaches to treating autoantibody-mediated disease in the nervous system will be briefly reviewed.

show abstract

Apheresis in treatment of acute inflammatory demyelinating disorders

Cited by 26 publications

References 36 publications

Therapeutic plasma exchange in paediatric neurology: a critical review and proposed treatment algorithm

Therapeutic plasma exchange in paediatric neurology: a critical review and proposed treatment algorithm

Caracterización de la mielitis transversa en un hospital referencia del sur colombiano

Autoantibodies and their potential roles in diseases of the nervous system

Contact Info

Product

Resources

About